DDOG vs LLY: Which Is the Better Buy?

Side-by-side comparison of Datadog, Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-17.
Datadog, Inc. · Technology
$261.09
+45.0% upside to fair value
Grade B High Quality
VS
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction Grade A High Quality
QuantHub Verdict
DDOG has more upside to fair value (+45.0%). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric DDOG LLY
Current Price $261.09 $1,179.09
Fair Value Estimate $378.58 $1,552.32
Upside to Fair Value +45.0% +31.7%
Market Cap $92.9B $1,110.4B
Forward P/E 678.5x
EV / EBITDA 410.4x 34.3x
Price / Sales 25.3x 14.6x
Price / FCF 86.1x 77.7x
Revenue Growth YoY +32.2% +55.5%
Gross Margin 79.9% 83.5%
Operating Margin -0.7% 45.9%
Return on Equity 3.8% 101.3%
Dividend Yield 0% 0.55%
FCF Yield 1.16% 1.29%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
DDOG — Datadog, Inc.
Datadog, Inc. is a leading provider of cloud-scale monitoring and analytics software for developers, IT operations teams, and business users in the technology sector. The company exhibits strong business quality with a durable competitive moat supported by high gross margins of 79.9% and rapid revenue growth of 32.2% in the most recent quarter. Despite this, the stock trades at a very high valuat…
LLY — Eli Lilly and Company
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Accumulation Zones
Metric DDOG LLY
Zone Low $283.94 $1,164.24
Zone High $321.79 $1,319.47
In Buy Zone? Yes Yes
← DDOG Research    LLY Research →    All Research